Ensysce Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 9
- Market Cap
- $5.4M
- Website
- http://www.ensysce.com
- Introduction
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, ta...
Ensysce Biosciences Announces Commercial Supplier for Breakthrou
Ensysce Biosciences secures GMP nafamostat supply for PF614-MPAR, accelerating clinical development and pipeline expansion with Aurore Life Sciences.
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose ...
Ensysce Biosciences secures GMP nafamostat supply for PF614-MPAR, ensuring supply chain security and accelerating clinical development.
Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection
Ensysce Biosciences secured future supply of GMP nafamostat from Aurore Life Sciences for PF614-MPAR, its overdose protection drug product, ensuring the supply chain and allowing reference to Aurore's Drug Master File. This agreement also benefits other nafamostat-based programs.
Ensysce Biosciences Announces Strategic Partnership for the Development and ...
Ensysce Biosciences announces strategic partnership with a specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR, aiming for swift regulatory approval and efficient product development.
Ensysce Biosciences Lands $10M Strategic Manufacturing Deal for Novel Pain Relief Pipeline
Ensysce Biosciences announces strategic partnership with a leading specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR, including a $10 million commitment and equity position.
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in ...
Ensysce Biosciences treated first group in PF614-MPAR-102 study, aiming for early interim data in 1Q 2025. PF614-MPAR received FDA Breakthrough Therapy designation, supported by a $14 million NIDA award. Ensysce targets reducing opioid abuse and overdose with its TAAP and MPAR platforms.
Ensysce Biosciences Launches Key Trial for Breakthrough Opioid Drug, Backed by $14M NIDA Grant
Ensysce Biosciences initiates dosing in PF614-MPAR-102 study, evaluating oxycodone and PF614 pharmacokinetics with nafamostat, funded by a $14 million NIDA award, with interim data expected in Q1 2025.
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
The article discusses the importance of enabling JavaScript for optimal app performance.
© Copyright 2024. All Rights Reserved by MedPath